KALA - Kala Pharmaceuticals Inc Stock Price, Fair Value and News

6.50USD-0.23 (-3.42%)Market Closed

Market Summary

USD6.50-0.23

Market Closed

-3.42%

KALA Stock Price

View Fullscreen

KALA RSI Chart

KALA Valuation

Market Cap

18.3M

Price/Earnings (Trailing)

-0.46

Price/Sales (Trailing)

3.79

Price/Free Cashflow

-0.63

KALA Price/Sales (Trailing)

KALA Profitability

Return on Equity

-593.77%

Return on Assets

-74.58%

Free Cashflow Yield

-158.89%

KALA Fundamentals

KALA Revenue

Revenue (TTM)

4.8M

KALA Earnings

Earnings (TTM)

-39.6M

Earnings Growth (Yr)

18.32%

Earnings Growth (Qtr)

-36.86%

Breaking Down KALA Revenue

Last 7 days

-5.8%

Last 30 days

-5.0%

Last 90 days

-8.3%

Trailing 12 Months

-62.6%

How does KALA drawdown profile look like?

KALA Financial Health

Current Ratio

4.22

Debt/Equity

4.28

Debt/Cashflow

-1.02

KALA Investor Care

Shares Dilution (1Y)

19.92%

Diluted EPS (TTM)

-17.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	4.8M
2022	9.3M	8.4M	5.7M	3.9M
2021	8.6M	10.8M	11.6M	11.2M
2020	5.8M	4.5M	5.3M	6.4M
2019	0	0	0	6.1M
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kala Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 04, 2024	iwicki mark t	sold	-30,547	6.73	-4,539	chief executive officer
Jan 04, 2024	reumuth mary	sold	-8,269	6.74	-1,227	chief financial officer
Jan 04, 2024	brazzell romulus k	sold	-10,898	6.74	-1,617	see remarks
Jan 04, 2024	iwicki mark t	acquired	-	-	14,300	chief executive officer
Jan 04, 2024	bazemore todd	acquired	-	-	6,500	see remarks
Jan 04, 2024	kharabi darius	sold	-9,321	6.73	-1,385	chief business officer
Jan 04, 2024	kharabi darius	acquired	-	-	4,600	chief business officer
Jan 04, 2024	bazemore todd	sold	-9,469	6.74	-1,405	see remarks
Jan 04, 2024	trachtenberg eric	acquired	-	-	4,600	see remarks
Jan 04, 2024	trachtenberg eric	sold	-8,269	6.74	-1,227	see remarks

Which funds bought or sold KALA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-16.04	-507	10,847	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	105,589	105,589	-%
May 15, 2024	Royal Bank of Canada	reduced	-63.49	-	-	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	new	-	568,823	568,823	0.04%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	258,615	2,124,910	0.03%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	0.55	117,162	1,045,880	-%
May 15, 2024	Board of Trustees of The Leland Stanford Junior University	unchanged	-	20,493	168,382	0.01%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-62.8	-17,580	12,919	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	116	956	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-95.71	-17,224	885	-%

Are Funds Buying or Selling KALA?

Are funds buying KALA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KALA

No. of Funds

Unveiling Kala Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	millennium management llc	5.0%	135,096	SC 13G
Feb 14, 2024	checkpoint capital l.p.	0%	0	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	9.99%	269,213	SC 13G/A
Jan 29, 2024	integrated core strategies (us) llc	4.9%	130,704	SC 13G/A
Oct 18, 2023	longitude capital partners ii, llc	2.3%	57,541	SC 13D/A
Jun 15, 2023	checkpoint capital l.p.	9.7%	228,032	SC 13G
Feb 14, 2023	longitude capital partners ii, llc	3.4%	57,541	SC 13D/A
Feb 14, 2023	baker bros. advisors lp	9.99%	180,913	SC 13G
Jan 17, 2023	integrated core strategies (us) llc	6.7%	107,200	SC 13G
Jun 03, 2022	ra capital management, l.p.	4.7%	3,412,868	SC 13D/A

Recent SEC filings of Kala Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 19, 2024	PRE 14A	PRE 14A
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 29, 2024	8-K	Current Report
Mar 29, 2024	424B5	Prospectus Filed
Mar 29, 2024	10-K	Annual Report

Peers (Alternatives to Kala Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Kala Pharmaceuticals Inc News

Latest updates

Kala Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2015Q4
Revenue	100.0%	1,075	538	-	420	2,100	1,372	1,856	3,067	3,051	3,266	2,238	2,220	833	1,071	1,180	1,451	2,057	1,386	-
Operating Expenses	24.0%	11,931	9,619	10,251	14,989	28,072	32,286	48,671	29,138	32,096	31,580	31,222	28,062	22,113	21,196	21,377	23,018	24,467	25,436	-
S&GA Expenses	-100.0%	-	4,623	5,831	9,549	22,673	26,982	24,027	25,349	27,986	27,699	26,466	23,893	15,301	15,408	14,492	15,280	17,007	18,236	-
R&D Expenses	-	6,351	-	-	5,391	4,473	4,466	-	2,881	3,094	3,126	3,397	3,468	6,053	5,434	6,138	7,070	7,108	6,959	-
Interest Expenses	-0.9%	1,455	1,468	1,577	1,447	2,207	2,035	2,076	2,072	2,091	2,141	2,170	2,157	2,134	2,128	2,113	2,180	2,125	2,094	-
Net Income	-36.9%	-11,807	-8,627	-12,843	29,073	-28,111	-32,941	-47,568	-28,127	-36,498	-30,412	-31,112	-27,948	-23,312	-21,955	-21,958	-23,176	-23,825	-25,388	-
Net Income Margin	6.3%	-8.20*	-8.75*	-11.52*	-13.84*	-16.29*	-15.53*	-12.69*	-10.85*	-11.69*	-13.18*	-	-	-	-	-	-	-	-	-
Free Cashflow	-40.9%	-10,844	-7,696	-14,279	-16,209	-25,963	-24,633	-28,448	-26,627	-22,152	-33,184	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.2%	53.00	56.00	61.00	67.00	72.00	87.00	86.00	85.00	112	139	194	215	230	222	225	246	259	154	161	179	197
Current Assets	-5.3%	50.00	53.00	58.00	66.00	71.00	86.00	85.00	84.00	98.00	124	149	172	179	171	178	197	210	105	112	133	150
Cash Equivalents	-4.7%	48.00	51.00	56.00	49.00	64.00	70.00	52.00	43.00	65.00	92.00	125	145	128	77.00	46.00	128	196	85.00	98.00	118	139
Inventory	-	-	-	-	-	-	-	-	0.00	11.00	9.00	8.00	8.00	8.00	5.00	8.00	6.00	5.00	5.00	-	8.00	5.00
Net PPE	-5.2%	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	-4.3%	46.00	48.00	50.00	49.00	49.00	68.00	87.00	117	117	123	132	131	120	122	119	117	117	125	118	118	115
Current Liabilities	42.3%	12.00	8.00	10.00	10.00	10.00	26.00	40.00	33.00	33.00	37.00	27.00	26.00	20.00	22.00	20.00	17.00	17.00	25.00	18.00	18.00	15.00
Long Term Debt	-16.6%	29.00	34.00	34.00	34.00	33.00	38.00	43.00	80.00	79.00	79.00	78.00	78.00	73.00	72.00	72.00	72.00	71.00	71.00	71.00	71.00	70.00
LT Debt, Current	-	6.00	-	-	-	-	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	34.00	34.00	34.00	33.00	38.00	43.00	80.00	79.00	79.00	78.00	78.00	73.00	72.00	72.00	72.00	71.00	71.00	71.00	71.00	70.00
Shareholder's Equity	-11.2%	7.00	8.00	11.00	17.00	23.00	19.00	-	-	-	17.00	61.00	84.00	110	100	106	129	142	30.00	43.00	61.00	82.00
Retained Earnings	-1.9%	-641	-629	-620	-612	-601	-587	-574	-603	-575	-542	-494	-466	-430	-399	-368	-340	-317	-295	-273	-250	-226
Additional Paid-In Capital	1.7%	648	637	632	630	625	606	573	572	570	559	556	551	540	500	475	470	459	325	317	311	309
Shares Outstanding	2.1%	3.00	3.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	34.00	-	-	-	20.00	-	-	-	254	-	-	-	412	-	-	-	160	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-40.9%	-10,844	-7,696	-2,952	-7,595	-9,684	-13,735	-15,665	-25,419	-24,089	-27,904	-26,083	-21,608	-32,640	-25,919	-25,641	-19,254	-19,880	-18,212	-22,912	-20,426	-31,170
Share Based Compensation	0.1%	2,376	2,374	2,403	1,362	1,324	960	1,327	1,916	2,805	2,748	3,928	4,710	4,702	4,063	3,978	2,774	2,497	2,325	2,572	2,621	2,473
Cashflow From Investing	-85.7%	-13.00	-7.00	9,719	-10,033	-108	51.00	64,911	2,828	-5,073	-4,623	4,721	22,674	48,031	36,842	-57,601	-57,158	-292	-188	-204	-499	-444
Cashflow From Financing	232.9%	8,440	2,535	40.00	3,073	2,858	31,786	-39,872	-10.00	154	160	1,230	5,849	35,315	20,722	746	7,979	131,181	6,295	2,668	-10.00	29.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KALA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Costs and expenses:
General and administrative	$ 5,422	$ 6,030
Research and development	6,351	4,036
(Gain) loss on fair value remeasurement of deferred purchase consideration		(230)
Loss (gain) on fair value remeasurement of contingent consideration	158	1,847
Total costs and expenses	11,931	11,683
Loss from operations	(11,931)	(11,683)
Other income (expense):
Interest income	504	675
Interest expense	(1,455)	(1,474)
Grant income	1,075
Other (expense) income, net		(1,973)
Total other income (expense)	124	(2,772)
Net loss	$ (11,807)	$ (14,455)
Net loss per share attributable to common stockholders-basic (in dollar per share)	$ (4.20)	$ (6.99)
Weighted average shares outstanding-basic (in shares)	2,813,210	2,069,186
Weighted average common shares outstanding -diluted (in shares)	2,813,210	2,069,186
Statement of Comprehensive Loss
Net loss	$ (11,807)	$ (14,455)
Other comprehensive loss:
Total comprehensive loss	$ (11,807)	$ (14,455)

KALA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 48,478	$ 50,895
Prepaid expenses and other current assets (Note 7)	1,609	1,975
Total current assets	50,087	52,870
Non-current assets:
Property and equipment, net	714	753
Right-of-use assets	1,945	2,025
Restricted cash and other long-term assets	287	301
Total assets	53,033	55,949
Current liabilities:
Accounts payable	732	919
Accrued expenses and other current liabilities	4,810	6,018
Deferred grant income		1,075
Current portion of lease liabilities	345	334
Current portion of long-term debt	5,992
Total current liabilities	11,879	8,346
Long-term liabilities:
Long-term lease liabilities	1,715	1,799
Long-term debt	28,510	34,190
Long-term contingent consideration	4,268	4,110
Total long-term liabilities	34,493	40,099
Total liabilities	46,372	48,445
Commitments and Contingencies (Note 17)
Stockholders' equity:
Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2023 and 2022; 2,759,372 and 1,706,971 shares issued and outstanding as of December 31, 2023 and 2022, respectively	3	3
Additional paid-in capital	647,874	636,910
Accumulated deficit	(641,216)	(629,409)
Total stockholders' equity	6,661	7,504
Total liabilities and stockholders' equity	$ 53,033	$ 55,949

About Kala Pharmaceuticals Inc

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

CEO	Mr. Mark T. Iwicki
WEBSITE	kalarx.com
INDUSTRY	Biotechnology
EMPLOYEES	34

Kala Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Kala Pharmaceuticals Inc? What does KALA stand for in stocks?

KALA is the stock ticker symbol of Kala Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kala Pharmaceuticals Inc (KALA)?

As of Fri May 17 2024, market cap of Kala Pharmaceuticals Inc is 18.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KALA stock?

You can check KALA's fair value in chart for subscribers.

What is the fair value of KALA stock?

You can check KALA's fair value in chart for subscribers. The fair value of Kala Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kala Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KALA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kala Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether KALA is over valued or under valued. Whether Kala Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Kala Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KALA.

What is Kala Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, KALA's PE ratio (Price to Earnings) is -0.46 and Price to Sales (PS) ratio is 3.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KALA PE ratio will change depending on the future growth rate expectations of investors.